Today, Biovitrum AB has been listed on the O list of the Stockholm Stock Exchange. Biovitrum is the fifty-third company to join the Nordic Exchange this year.
Biovitrum AB is a biopharma company with operations in Sweden and in the UK. The company conducts research and develops pharmaceuticals for the treatment of obesity, diabetes, inflammation and blood diseases. Biovitrum also develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has a turnover of approximately SEK 1 billion and some 500 employees.
”It is very gratifying to welcome Biovitrum to the Nordic Exchange. Biovitrum strengthens our Swedish and Danish cluster of pharmaceutical companies and gives investors worldwide another interesting investment option,” says Jenny Rosberg, President of Company Services, OMX.
A filmed interview with Biovitrum’s President and Chief Executive Officer Mats Pettersson is available on the Stockholm Stock Exchange website, www.omxgroup.com/stockholmsborsen. Photographs will be available on www.omxgroup.com/stockholmsborsen under Corporate actions and Changes in listed companies/Listings.
A round lot of shares in Biovitrum, whose short name is BVT, amounts to 100 and the company is included in the Health Care sector.
About OMX
OMX is a leading expert in the exchange industry. Through the Nordic Exchange in Copenhagen, Stockholm, Helsinki, Riga, Tallinn and Vilnius, OMX offers access to approximately 80 percent of the Nordic and Baltic securities market. Our integrated technology solutions span the entire transaction chain enabling efficient securities transactions for exchanges, clearing organizations, central securities depositories and other financial institutions around the world. OMX is listed on the Nordic Exchange in Stockholm, Helsinki and Copenhagen. For more information please visit www.omxgroup.com
